On the Design of Combination Cancer Therapy
James H Doroshow1, Richard M Simon2
1Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, USA; Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Abstract:
Combination therapy programs are the hallmark of the successful treatment of all forms of human malignancies. In this issue of Cell, Palmer and Sorger present data suggesting that cell culture results indicative of synergistic anticancer drug interactions rarely translate clinically and that the results of combination therapies in mouse models or human clinical trials, even if successful, are best explained by the independent activities of the individually administered drugs.
Insights
Combination cancer therapy shows limited clinical synergy. Studies suggest that even successful treatments often work through individual drug effects, not combined interactions, challenging current approaches to cancer drug development.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Background:
- Combination therapy is standard for treating human malignancies.
- Synergistic drug interactions are sought to improve treatment efficacy.
Purpose of the Study:
- To evaluate the clinical translation of synergistic anticancer drug interactions observed in vitro.
- To determine if combination therapy success is due to synergy or independent drug action.
Main Methods:
- Analysis of cell culture data for synergistic drug interactions.
- Review of results from mouse models and human clinical trials of combination therapies.
Main Results:
- In vitro synergistic drug interactions rarely translate to clinical efficacy.
- Successful combination therapies are often explained by the additive effects of individual drugs.
- Clinical outcomes do not consistently support in vitro synergy findings.
Conclusions:
- The clinical relevance of in vitro synergistic anticancer drug interactions is questionable.
- Independent drug activities are a more likely explanation for successful combination therapies.
- Rethinking preclinical models and clinical trial analysis for combination cancer treatments is warranted.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers
